Evidence map›Paper›PMID 7706474›Full record

ArticleThe Journal of clinical investigation1995

Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

E H Chen, E E Johnson, S M Vetter, B S Mitchell

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pharmacogenetics and pharmacoepigenetics of gemcitabine.Medical oncology (Northwood, London, England) · 2010
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

E H ChenDepartment of Pharmacology, University of North Carolina, Chapel Hill 27599, USA.
E E Johnson
S M Vetter
B S Mitchell
University of North Carolina at Chapel Hill · US

Funding

NUCLEOSIDE AND NUCLEOTIDE METABOLIZING ENZYMESR01CA034085 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI MITCHELL, BEVERLY SHRIVER · 1985 to 2004
$1.6M
NCI NIH HHS 1-RO1-CA34085
6 · The paper itself

Abstract

Deoxycytidine kinase (dCK) phosphorylates 2'-deoxycytidine, as well as the purine deoxyribonucleosides and a number of nucleoside analogues that are important in the chemotherapy of leukemias. The enzyme is highly expressed in the thymus relative to other tissues and may play an important role in the T cell depletion associated with adenosine deaminase and purine nucleoside phosphorylase deficiencies. To characterize the dCK promoter region and to determine whether it mediates higher levels of gene expression in T lymphoblasts, we have analyzed a 700-bp genomic fragment encompassing 548 bp of 5' flanking region for functional activity and for transcription factor binding using T and B lymphoblast cell lines and nuclear extracts. The regions of the promoter that were defined as important to its function include a 5' GC box, and E box, a 3' GC box, and an E2F site. The transcription factor Sp1 binds to both GC boxes, activating at the 5' site but repressing at the 3' site. MLTF/USF activates transcription through the E box, whereas E2F activates through the E2F site, but binds weakly to this site in vitro and does not appear to mediate cell cycle-specific expression of dCK in vivo. No significant differences in promoter activity or transcription factor binding were observed between Jurkat T and Raji B lymphoblasts. The promoter of the dCK gene is thus regulated by a number of ubiquitously expressed transcription factors. DCK expression in cultured lymphoblast cell lines is not solely a function of the T or B lineage derivation.

Indexed as

Gene Expression RegulationBase SequenceBinding SitesB-LymphocytesCell LineDeoxycytidine KinaseDNA Mutational AnalysisHematopoietic Stem CellsHumansLymphocytesMolecular Sequence DataMutagenesis, Site-DirectedPromoter Regions, GeneticProtein BindingRecombinant Fusion ProteinsSequence DeletionDeoxycytidine KinaseRecombinant Fusion ProteinsTranscription Factors

Identifiers

PMID7706474
PMCPMC295671
OpenAlexW1995927666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.